skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by pro-inflammatory cytokines: potential drug targets

Review

(1540) Views  (2088) Full article downloads

Authors: Charles J Malemud

Published Date October 2010 Volume 2010:2 Pages 97 - 111
DOI: http://dx.doi.org/10.2147/IJICMR.S9470

Charles J Malemud
Arthritis Research Laboratory, Division of Rheumatic Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Abstract: Although several pro-inflammatory cytokines including interleukin-6 (IL-6), IL-7, IL-12/IL-23, IL-17, IL-2, interferon, and the anti-inflammatory cytokines, IL-4/IL-13, IL-10, and IL-22, all activate the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, in autoimmune disorders, a skewing of the cytokine repertoire in favor of pro-inflammatory cytokines results in amplifying the effects of pro-inflammatory cytokines. An apparent deficiency of anti-inflammatory cytokines to counterbalance the ‘ramping up’ of pro-inflammatory cytokine-mediated activation of JAK/STAT is also significant, while endogenous negative regulators of cytokine signaling and JAK/STAT activation may also be compromised. In addition, JAK/STAT pathway activation can result in activation of stress-activated protein/mitogen-activated protein kinase (SAP/MAPK) and phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin pathways that are instrumental in promoting matrix metalloproteinase gene expression, aberrant cell survival, and osteoclast differentiation. The critical role played by pro-inflammatory cytokines in differentially activating JAK/STAT and parallel signal transduction pathways resulted in the development of several cytokine/cytokine receptor neutralizing monoclonal antibodies and fusion proteins that are currently employed for treating rheumatoid arthritis, Crohn’s disease, and psoriasis. Small molecule inhibitors (SMIs) that target specific JAK enzymes have led to the development of CP690550, a JAK3-specific SMI, which is the first JAK-specific SMI to reach phase III in a rheumatoid arthritis clinical trial.

Keywords: autoimmunity, cytokines, inflammation, Janus kinase, signal transducers and activators of transcription, small molecule inhibitors






Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice
Dendritic cells in infectious disease, hypersensitivity, and autoimmunity
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
Zinc oxide nanoparticles as selective killers of proliferating cells
Erratum
A case of recurrent bloody tears
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy